Sebastian A. Brunemeier is a biotech founder and VC investor. He is CEO and Co-Founder of ImmuneAGE Pharma, a stealth-mode company developing small molecules for immune rejuvenation. Previously, he was Co-Founder and Chief Investment Officer at Cambrian Biopharma and a Principal at Apollo Health Ventures, the first and largest aging-focused venture capital fund in the world.
Sebastian was CEO of Cyclone Therapeutics, a Scripps Research Institute spinout focused on proteostasis. He was co-founder and COO of Samsara Therapeutics, a biotech focused on autophagy-enhancing small molecule drug discovery in Oxford, UK. He was a Fulbright Fellow in the biology of aging at the Gulbenkian Institute, a Skaggs-Oxford Scholar at the Scripps Research Institute, and a SENS Foundation Scholar at the Buck Institute for Research on Aging.
His education includes partial DPhil (PhD) training on the biochemistry of aging at the University of Oxford as a Clarendon Scholar, an MSc in Life Science Business Management and an MSc in Molecular Neuroscience from the University of Amsterdam. He served as a board member at Revivo Therapeutics, a trustee of the British Society for Research on Aging, and an advisor to McKinsey & Company.